Abzena plots 6th bi­o­log­ics plant as de­mand for mam­malian cell-line pro­duc­tion con­tin­ues to grow

With de­mand for bi­o­log­ics man­u­fac­tur­ing at an all-time high, UK CD­MO Abzena has rushed to add a big­ger foot­print to keep up. Now look­ing to ex­pand its US pres­ence, Abzena will tack on an­oth­er man­u­fac­tur­ing site — its third state­side.

Abzena said the ex­pan­sion, which will be its sixth site, was dri­ven by in­creased cus­tomer de­mand for com­mer­cial-scale man­u­fac­tur­ing ca­pac­i­ties across a wide ar­ray of ther­a­peu­tic ar­eas. The site’s ex­act lo­ca­tion in the US wasn’t dis­closed, but Abzena said it will in­crease its cGMP man­u­fac­tur­ing ca­pac­i­ty by adding four mod­u­lar suites, each of which will house two 2,000-liter biore­ac­tors in the first phase of con­struc­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.